Chloroquine diphosphate

ApprovedSmall molecule

UUniversity of Sao Paulo General Hospital

Chloroquine diphosphate is one of 116 small molecule programs targeting Metastasis. It is currently in Approved.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

Severe Acute Respiratory SyndromeActive, not recruiting

Autoimmune HepatitisActive, not recruiting

COVID-19Active, not recruiting

MetastasisPreclinical

Active, not recruiting

Severe Acute Respiratory SyndromePhase 2

Active, not recruiting

Autoimmune HepatitisApproved

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Chloroquine diphosphate

UUniversity of Sao Paulo General Hospital

Approved

1 2

Aldactone

Pfizer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Tricor

JJagotec

Preclinical

1 5

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

SARS-COV-2 VACCINE

Moderna

Preclinical

2 8

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—9

Piperacillin/tazobactam

Pfizer

Preclinical

1 10

Orap

Teva

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autoimmune Hepatitis2 trials

Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial

Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT02463331·57 enrolled

CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS

Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT01980745·61 enrolled

COVID-191 trial

Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection

Completed·FFundação de Medicina Tropical Dr. Heitor Vieira Dourado·Phase 2·NCT04342650·152 enrolled

Metastasis1 trial

IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy

Completed·MMain Line Health·N/A·NCT01727531·20 enrolled

Severe Acute Respiratory Syndrome1 trial

Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2

Completed·FFundação de Medicina Tropical Dr. Heitor Vieira Dourado·Phase 2·NCT04323527·278 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Chloroquine diphosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chloroquine diphosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chloroquine diphosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Sao Paulo General Hospital

Chloroquine diphosphate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autoimmune Hepatitis2 trials

COVID-191 trial

Metastasis1 trial

Severe Acute Respiratory Syndrome1 trial

References

Drug Info

Quick Facts

Related News